Focused On-demand Library for Melanocyte-stimulating hormone receptor

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Melanocortin receptor 1

Alternative UPACC:

Q01726; Q66K38; Q6UR93; Q8WWX6; Q8WWX7; Q96I33; Q96RU4; Q9UBF7; Q9UN58; Q9UN59; Q9UN60; Q9UN61; Q9UN62


The Melanocyte-stimulating hormone receptor, also known as Melanocortin receptor 1, plays a pivotal role in skin pigmentation. It binds to melanocortin, including MSH and ACTH, triggering a cascade via G proteins that activates adenylate cyclase, crucial for melanogenesis. This process regulates the production of eumelanin and phaeomelanin, determining skin, hair, and eye color.

Therapeutic significance:

Given its association with cutaneous malignant melanoma 5, understanding the Melanocyte-stimulating hormone receptor's function could unveil novel therapeutic avenues. Its role in melanogenesis makes it a potential target for treatments aimed at modulating pigmentation disorders and skin cancer.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.